Treatment with nucleos(t)ide analogues in chronic hepatitis B: Where does the road map lead us?

Journal of Hepatology

Volumn 51, Issue 1, 2009, Pages 1-3

  Janssen, Harry L A ^a   Reijnders, Jurriën G P ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; EMTRICITABINE; ENTECAVIR; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; NUCLEOSIDASE; TELBIVUDINE; TENOFOVIR; VIRUS DNA;

ANTIVIRAL RESISTANCE; CHRONIC HEPATITIS; CLINICAL PROTOCOL; CLINICAL TRIAL; EDITORIAL; HEPATITIS B; HUMAN; MONOTHERAPY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; TREATMENT OUTCOME;

ANTIVIRAL AGENTS; DNA, VIRAL; HEPATITIS B E ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; NUCLEOSIDES; PYRIMIDINONES;

EID: 67349115364     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2009.04.007     Document Type: Editorial

References (24)

1. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 11 (2004) 97-107
2. Chen C.J., Yang H.I., Su J., Jen C.L., You S.L., Lu S.N., et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 295 (2006) 65-73
3. Iloeje U.H., Yang H.I., Su J., Jen C.L., You S.L., and Chen C.J. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 130 (2006) 678-686
4. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 50 (2009) 227-242
5. Dienstag J.L., Cianciara J., Karayalcin S., Kowdley K.V., Willems B., Plisek S., et al. Durability of serologic response after lamivudine treatment of chronic hepatitis B. Hepatology 37 (2003) 748-755
6. Hadziyannis S.J., Tassopoulos N.C., Heathcote E.J., Chang T.T., Kitis G., Rizzetto M., et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med 352 (2005) 2673-2681
7. Song B.C., Suh D.J., Lee H.C., Chung Y.H., and Lee Y.S. Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. Hepatology 32 (2000) 803-806
8. Liaw Y.F., Sung J.J., Chow W.C., Farrell G., Lee C.Z., Yuen H., et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 351 (2004) 1521-1531
9. Keeffe E.B., Zeuzem S., Koff R.S., Dieterich D.T., Esteban-Mur R., Gane E.J., et al. Report of an international workshop: roadmap for management of patients receiving oral therapy for chronic hepatitis B. Clin Gastroenterol Hepatol 5 (2007) 890-897
10. Zoulim F., Durantel D., and Deny P. Management and prevention of drug resistance in chronic hepatitis B. Liver Int 29 (2009) 108-115
11. Lai C.L., Gane E., Liaw Y.F., Hsu C.W., Thongsawat S., Wang Y., et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 357 (2007) 2576-2588
12. Locarnini S., Qi X., Arterburn S., Snow A., Brosgart C., Currie G., et al. Incidence and predictors of emergence of adefovir resistant HBV during 4 years of adefovir dipivoxil (ADV) therapy for patients with chronic hepatitis B (CHB) (abstract). J Hepatol 42 (2005) 17
13. Yuen M.F., Sablon E., Hui C.K., Yuan H.J., Decraemer H., and Lai C.L. Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. Hepatology 34 (2001) 785-791
14. Zeuzem S., Gane E., Liaw Y.-F., Lim S.G., DiBisceglie A., Buti M., et al. Baseline characteristics and on-treatment response predict the outcomes of 2 years telbivudine treatment of chronic hepatitis B. J Hepatol 51 (2009) 11-20
15. Heathcote E.J., Gane E., De Man R., Chan S., Sievert W., Mauss S., et al. Two year tenofovir disoproxil fumarate (TDF) treatment and adefovir dipivoxil (ADV) switch data in HBeAg-positive patients with chronic hepatitis B (study 103), preliminary analysis. Hepatology 48 (2008) A158
16. Marcellin P., Buti M., Krastev Z., Gurel S., Balabanska R., Dusheiko G., et al. Two year tenofovir disoproxil fumarate (TDF) treatment and adefovir dipivoxil (ADV) switch data in HBeAg-negative patients with chronic hepatitis B (study 102), preliminary analysis. Hepatology 48 (2008) A146
17. Tenney DJ, Rose RE, Baldick CJ, Pokornowski KA, Eggers BJ, Fang J, et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology 2009. [Epub ahead of print].
18. Yuen M.F., Fong D.Y., Wong D.K., Yuen J.C., Fung J., and Lai C.L. Hepatitis B virus DNA levels at week 4 of lamivudine treatment predict the 5-year ideal response. Hepatology 46 (2007) 1695-1703
19. Snow A., Chappell B., Curtis M., Zhu Y., Heathcote E.J., Marcellin P., et al. Week 96 resistance surveillance for HBeAg-positive and negative subjects with chronic HBV infection randomized to receive tenofovir DF 300 mg QD. Hepatology 48 (2008) A977
20. Standring D.N., Bridges E.G., Placidi L., Faraj A., Loi A.G., Pierra C., et al. Antiviral beta-l-nucleosides specific for hepatitis B virus infection. Antivir Chem Chemother 12 (2001) 119-129
21. Liaw Y.F., Gane E., Leung N., Zeuzem S., Wang Y., Lai C.L., et al. 2-Year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology 136 (2009) 486-495
22. Lampertico P., Vigano M., Facchetti F., Puoti M., Minola E., Suter F., et al. Effectiveness of entecavir for the treatment of NUC-naive chronic hepatitis B patients: a large multicenter cohort study in clinical practice. Hepatology 48 (2008) A896
23. Reijnders JGP, Deterding K, Petersen J, Zoulim F, Santantonio T, Buti M, et al. Antiviral effect of entecavir: results from 160 chronic hepatitis B patients in an international multicenter cohort study. In: The 44th annual meeting of the European Association for the Study of the Liver (EASL). Copenhagen, Denmark 2009.
24. Van Bommel F., De Man R., Stein K., Huppe D., Petersen J., Buggisch P., et al. A multicenter analysis of antiviral response after one year of tenofovir monotherapy in HBV-monoinfected patients with prior nucleos(t)ide analog experience. J Hepatol 48 (2008) A73